CN116966233A - Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof - Google Patents
Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof Download PDFInfo
- Publication number
- CN116966233A CN116966233A CN202310750321.2A CN202310750321A CN116966233A CN 116966233 A CN116966233 A CN 116966233A CN 202310750321 A CN202310750321 A CN 202310750321A CN 116966233 A CN116966233 A CN 116966233A
- Authority
- CN
- China
- Prior art keywords
- cistanche
- extract
- parts
- health
- yang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000005787 Cistanche Species 0.000 title claims abstract description 55
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 27
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 238000005728 strengthening Methods 0.000 title claims abstract description 16
- 150000004676 glycans Chemical class 0.000 claims description 32
- 229920001282 polysaccharide Polymers 0.000 claims description 32
- 239000005017 polysaccharide Substances 0.000 claims description 32
- 229920002472 Starch Polymers 0.000 claims description 30
- 239000008107 starch Substances 0.000 claims description 30
- 235000019698 starch Nutrition 0.000 claims description 30
- 239000000047 product Substances 0.000 claims description 29
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 25
- 244000182216 Mimusops elengi Species 0.000 claims description 25
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 25
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 16
- 229910052708 sodium Inorganic materials 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 15
- 241000336291 Cistanche deserticola Species 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 235000000346 sugar Nutrition 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- 235000010804 Maranta arundinacea Nutrition 0.000 claims description 12
- 244000145580 Thalia geniculata Species 0.000 claims description 12
- 235000012419 Thalia geniculata Nutrition 0.000 claims description 12
- 235000020696 epimedium extract Nutrition 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 11
- 241000893536 Epimedium Species 0.000 claims description 10
- 244000046146 Pueraria lobata Species 0.000 claims description 10
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 10
- 235000018905 epimedium Nutrition 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 238000000967 suction filtration Methods 0.000 claims description 8
- 238000007873 sieving Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013049 sediment Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 239000007779 soft material Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 4
- 241000700159 Rattus Species 0.000 description 26
- 230000036541 health Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 150000003254 radicals Chemical class 0.000 description 13
- 210000001320 hippocampus Anatomy 0.000 description 10
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 6
- 229940118019 malondialdehyde Drugs 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000336315 Cistanche salsa Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007074 memory dysfunction Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and a preparation method thereof, and particularly relates to the technical field of traditional Chinese medicine preparation.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicine preparation, in particular to a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and a preparation method thereof.
Background
Alzheimer's disease, also known as senile dementia, is an age-related neurodegenerative disease, which is mainly clinically manifested by memory dysfunction and changes in behavior, and with the aggravation of aging population, the number of AD patients increases sharply, bringing great burden to society and families;
with the progress of society, the life of human beings is prolonged, the aging society comes in, senile diseases are more and more prominent, the incidence of dementia is increased year by year, the senile diseases can be interpreted as Alzheimer disease, the severity is increased continuously, great pain is caused to patients, great burden is caused to families and society, no good prevention and treatment method exists in the domestic and international medical community at present, and medical workers for researching dementia are seriously puzzled;
in practical application, the health care product prepared based on cistanche deserticola has single component, is a yang tonifying medicine and has a certain health care effect, but in the process of preparing the cistanche deserticola health care product at present, the active ingredients in the cistanche deserticola are usually extracted and then proportioned to prepare the health care product, and the extraction of polysaccharide ingredients in the cistanche deserticola can improve the learning and memory capacity of the patients suffering from Alzheimer disease, enhance the self immunity of the patients, but inevitably cause partial nutrient loss, even if the addition of medicinal materials is carried out, the mutual interference and rejection among medicinal material properties are inevitably caused, so that polysaccharide ingredients in the cistanche deserticola cannot be fused with the cistanche deserticola, and the condition of modification of polysaccharide ingredients in the cistanche deserticola is easily caused, so that each nutrient ingredient in the prepared health care product is difficult to be absorbed by a human body, and how to enhance the health care effect of the cistanche deserticola health care product is the current urgent need.
In view of the above, the invention provides a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and a preparation method thereof.
Disclosure of Invention
In order to overcome the defects in the prior art, the invention provides a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and a preparation method thereof, and the technical problems to be solved by the invention are as follows: the extraction of polysaccharide components in cistanche can improve the learning and memory capacity of Alzheimer's disease patients, strengthen the self-immunity of the patients, but inevitably cause partial nutrient loss, even if the addition of medicinal materials is carried out, the mutual interference and rejection among the medicinal materials are inevitably caused, so that the polysaccharide components in cistanche cannot be fused with the medicinal materials, and the condition of modification of the polysaccharide components in cistanche is easily caused, so that each nutrient component in the prepared health care product is difficult to be absorbed by human bodies.
The purpose of the invention is as follows: the health-care product tablet prepared from cistanche, medlar, epimedium herb, kudzuvine root, starch, powdered sugar, magnesium stearate, microcrystalline cellulose and carboxymethyl starch sodium has the effects of tonifying kidney yang and replenishing vital essence and blood by collocation of raw materials, and further, experimental analysis verifies that the cistanche polysaccharide can improve the learning and memory capacity of Alzheimer disease patients, strengthen the autoimmunity of the patients, and is realized by reducing the damage of oxygen free radicals and accelerating the elimination of free radicals in bodies, so that the tablet has a certain effect of preventing senile dementia and has good application prospect.
In order to achieve the above purpose, the present invention provides the following technical solutions: a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia comprises the following raw materials:
50-60 parts of cistanche, 5-7 parts of medlar, 3-5 parts of epimedium, 3-6 parts of kudzuvine root, 3-7 parts of starch, 2-4 parts of sugar powder, 3-4 parts of magnesium stearate, 2-3 parts of microcrystalline cellulose and 1-2 parts of sodium carboxymethyl starch.
A preparation method of a yang-strengthening health-preserving cistanche health-care product for preventing senile dementia comprises the following steps:
s1, firstly, preparing medicinal materials, namely preparing medlar extract, cistanche extract, epimedium extract and arrowroot, and respectively placing the medlar extract, the cistanche extract, the epimedium extract and the arrowroot in different containers for standby;
s2, uniformly mixing starch, powdered sugar, microcrystalline cellulose and sodium carboxymethyl starch, and sieving with a 80-mesh sieve to serve as auxiliary materials for later use;
s3, adding the auxiliary materials prepared in the S2 into the medlar extract, the cistanche extract, the epimedium extract and the arrowroot prepared in the S1, granulating, drying and tabletting to prepare finished tablets;
s4, polysaccharide extraction operation is carried out on the finished product tablets in the step S3, and experimental analysis is carried out.
As a further aspect of the invention: the preparation method of the medlar extract in the step S1 comprises the following steps:
5-7 parts of medlar are placed in a container, 10 times of water is added for ultrasonic extraction for 30min at 70 ℃, suction filtration is carried out, 8 times of water is added for ultrasonic extraction for 30min, suction filtration is carried out, 2 times of filtrate is combined, and the mixture is concentrated into 1g/ml extract.
As a further aspect of the invention: the preparation method of the cistanche extract in the step S1 comprises the following steps:
slicing 50-60 parts of cistanche deserticola, placing in a round bottom flask, adding 8 times of 70% ethanol, ultrasonically extracting for 45min, performing suction filtration, adding 6 times of 70% ethanol into residues, performing secondary extraction, performing suction filtration, mixing 2 times of filtrates, and concentrating to obtain extract of 1 g/ml.
As a further aspect of the invention: the preparation method of the epimedium extract in the step S1 comprises the following steps:
placing 3-5 parts of herba Epimedii in a round bottom flask, adding 10 times of 70% ethanol, ultrasonic extracting for 30min, vacuum filtering, adding 8 times of 70% ethanol into the residue, extracting again, vacuum filtering, mixing 2 times of filtrates, and concentrating to obtain extract of 1 g/ml.
As a further aspect of the invention: the preparation method of the arrowroot flour in the step S1 comprises the following steps:
pulverizing 3-6 parts of radix Puerariae, and sieving with 80 mesh sieve.
As a further aspect of the invention: the specific implementation steps of the S3 are as follows:
s301, adding the prepared auxiliary materials into medlar extract, cistanche extract, epimedium extract and arrowroot to be uniformly mixed, preparing soft materials, and granulating by a 18-mesh sieve to form wet granules;
s302, drying wet particles for 2 hours at 80 ℃ and sieving the wet particles with a 18-mesh sieve to obtain particles;
s303, adding sodium carboxymethyl starch and 0.2% magnesium stearate into the granules after the granule finishing, uniformly mixing, and tabletting.
As a further aspect of the invention: the polysaccharide extraction in the step S4 is implemented as follows:
s401, soaking the tablets in hot ethanol for 3 hours, filtering with gauze, discarding filtrate, and leaving residues;
s402, adding water into the generated residues to decoct for 3 times, each time for 1-2 hours, filtering and combining the filtrates;
s403, evaporating and concentrating the filtrate, centrifuging to remove sediment, precipitating supernatant with 95% ethanol with 2-3 times of volume, standing at 4deg.C for 24h, centrifuging at 4deg.C for 20min, centrifuging at 5500-6000r/min, and collecting sediment;
s404, re-dissolving the precipitate with water, deproteinizing, dialyzing, and freeze-drying to obtain crude polysaccharide;
s405, performing experimental analysis by using polysaccharide.
The invention has the beneficial effects that: the health care product tablet prepared from cistanche, medlar, epimedium, kudzuvine root, starch, sugar powder, magnesium stearate, microcrystalline cellulose and sodium carboxymethyl starch has the effects of tonifying kidney yang and replenishing essence and blood by matching raw materials, and further, experimental analysis verifies that the cistanche polysaccharide can improve the learning and memory capacity of patients suffering from Alzheimer disease and strengthen the immunity of the patients, and the cistanche polysaccharide can be fused with the health care product prepared from medlar, epimedium, kudzuvine root, starch, sugar powder, magnesium stearate, microcrystalline cellulose and sodium carboxymethyl starch by matching with the health care product prepared from medlar, the starch, the sugar powder, the magnesium stearate, the microcrystalline cellulose and the sodium carboxymethyl starch, so that the polysaccharide in the cistanche can not cause modification condition to the polysaccharide in the cistanche, and the nutrient in the health care product is fully absorbed by human body, and the effects of enhancing the health care effect of the cistanche health care product are realized by reducing the damage of oxygen free radicals and accelerating the removal of free radicals in the body, so that the cistanche health care product has a certain effect of preventing senile dementia and good application prospect.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Examples:
formula I: the raw materials comprise 55 parts of cistanche, 5 parts of medlar, 3 parts of epimedium herb, 5 parts of kudzuvine root, 4 parts of starch, 3 parts of powdered sugar, 3 parts of magnesium stearate, 2 parts of microcrystalline cellulose and 1 part of sodium carboxymethyl starch.
And the formula II: 50 parts of cistanche, 6 parts of medlar, 4 parts of epimedium herb, 6 parts of kudzuvine root, 4 parts of starch, 2 parts of powdered sugar, 4 parts of magnesium stearate, 2 parts of microcrystalline cellulose and 1 part of sodium carboxymethyl starch.
And the formula III: 60 parts of cistanche, 5 parts of medlar, 3 parts of epimedium herb, 3 parts of kudzuvine root, 6 parts of starch, 2 parts of sugar powder, 3 parts of magnesium stearate, 2 parts of microcrystalline cellulose and 2 parts of sodium carboxymethyl starch.
And a formula IV: 52 parts of cistanche, 6 parts of medlar, 5 parts of epimedium herb, 5 parts of kudzuvine root, 7 parts of starch, 3 parts of sugar powder, 3 parts of magnesium stearate, 3 parts of microcrystalline cellulose and 1 part of sodium carboxymethyl starch.
Formula five: 58 parts of cistanche, 5 parts of medlar, 3 parts of epimedium herb, 5 parts of kudzuvine root, 4 parts of starch, 2 parts of sugar powder, 3 parts of magnesium stearate, 2 parts of microcrystalline cellulose and 2 parts of sodium carboxymethyl starch.
The preparation method comprises the following steps:
processing the raw materials to prepare a medlar extract, a cistanche extract, an epimedium extract and arrowroot, uniformly mixing starch, powdered sugar, microcrystalline cellulose and sodium carboxymethyl starch, sieving with a 80-mesh sieve, taking the mixture as an auxiliary material for standby, adding the auxiliary material prepared in the step S2 into a plurality of medlar extract, cistanche extract, epimedium extract or arrowroot prepared in the step S1, granulating, drying and tabletting to obtain the finished tablet.
The test was performed using tablets made with five formulations:
polysaccharide extraction operations were performed on the finished tablets of formula one and experimental analysis was performed:
building an animal model:
taking 80 Wistar rats, weighing 180-220g, injecting chloral hydrate (0.35 g/kg) into abdominal cavity for anesthesia, fixing on brain stereotactic instrument, removing hair from the top of the head, sterilizing skin, cutting the center of the top of the head, exposing bregma, vertically injecting needle from brain surface by microinjector at right side of midline after bregma according to rat brain standing map, and slowly injecting 2 mu l Abeta into lateral ventricle 1-40 The needle was left to ensure adequate diffusion of the injection solution, and the needle was slowly withdrawn after all steps were sterile, penicillin was used to sterilize the skin incision, the wound was sutured, and the sham group was injected with an equal amount of saline.
Experimental animal grouping and specimen acquisition:
the experimental rats are randomly divided into a normal control group, a model group and a drug intervention group, 10 rats in each group are subjected to gastric lavage with low, medium and high doses of polysaccharide every day after model preparation, the normal rats and the model group are subjected to gastric lavage with equal amounts of corn oil for 7 days, all animals are killed by a cervical dislocation method after observation, bilateral hippocampus of the rats are taken, and the rats are washed and stored with ice physiological saline, and indexes such as SO, MDA, NO and ROS expression in the hippocampus are detected.
Morris water maze experiment:
each group of rats was subjected to Morris water maze test respectively at preoperative 7d, postoperative 7d and postoperative 28d, the test procedure was a positioning navigation test for 3d, the previous 2d was a training adaptation period, each day of the morning and afternoon was 2 times, the rats were put into the water from 4 water inlet points facing the pool wall in turn during training in the clockwise direction, the time required for finding and climbing up the platform was recorded, namely the escape latency, the day 3 was recorded, if the rats found the platform within 1min, the actual escape latency was recorded, if the rats did not find the platform within 1min, the experimenter led the rats to the platform and stayed for 15s, and the escape latency was recorded as 1min.
And (3) experimental detection:
superoxide dismutase (SOD) level detection:
mixing fresh Hippocampus tissue of rat with reagent, standing at 37deg.C in constant temperature water bath for 40min, standing at room temperature for 10min, zeroing at 550nm with 0.5cm optical path and distilled water, and measuring absorbance of each tube with 752P ultraviolet-visible spectrophotometer;
malondialdehyde (MDA) level determination:
mixing fresh Hippocampus and reagent, cooling with 95 deg.C water bath for 40min, taking out, cooling with running water, centrifuging for 10min with 40000r/min, collecting supernatant, measuring optical path at 532nm, zeroing with distilled water, and measuring absorbance value of each tube with 752P ultraviolet-visible spectrophotometer;
detection of induced release of free radicals in rat hippocampus:
homogenizing the tissues of fresh hippocampus of each group of rats, centrifuging to obtain supernatant, immediately measuring the content of free radicals, and performing the measurement according to a literature method and according to the operation instructions of a kit;
statistical analysis:
mean ± standard deviation of experimental dataThe data were analyzed using the ANOVA and t-test, SPSS13.0 statistical software for group comparisons.
Analysis of results:
AD rat learning memory capacity assay:
the incubation period of rats in each group before operation is not different, on the 7 th day after operation, the incubation periods of normal groups and sham operation groups are not obviously different from those before operation, but the cognitive function of rats in other groups is obviously prolonged compared with those before operation, and compared with the results of the normal groups and the sham operation groups, the difference has significance (P < 0.01); after 28d of postoperative gastric lavage administration treatment, the latency of the normal group and the sham operation group is not significantly different from that before operation, and the model group is still obviously prolonged compared with the former two groups, which indicates that the cognitive function of the model group is still worse, the latency of the cistanche polysaccharide treatment group rats is obviously reduced compared with that of the rat after operation by 7d, the difference is significantly significant (P < 0.01) compared with the model group, which indicates that the cognitive function of the rats is improved after cistanche polysaccharide treatment, and the method is specifically shown in table 1:
table 1-effect of cistanche polysaccharide on learning and memory of AD rats:
p <0.01 compared to normal and sham groups; comparison with model group #P < 0.01.
MDA content and SOD activity determination:
the difference between the cistanche polysaccharide and the cistanche polysaccharide in each dose group is significant (P < 0.01) compared with the model control group; each dose group of cistanche salsa can increase SOD activity and reduce MDA content, and is shown in table 2 specifically:
table 2-effect of cistanche polysaccharide on AD rat brain tissue free radical:
| group of | MDA(nmol/ml) | SOD(IU/ml) |
| Normal group | 3.61±1.27 | 149.10±5.93 |
| False operation group | 3.46±1.64 | 151±4.16 |
| Model group | 20.53±3.34* | 84.79±7.7* |
| Low dose group | 8.67±2.67# | 128.75±11.67# |
| Medium dose group | 4.35±0.23# | 146.25±8.36# |
| High dose group | 3.36±1.26# | 152.36±8.28# |
P <0.01 compared to normal and sham groups; comparison with model group #P < 0.01.
Hippocampal release NO and ROS activity assay:
quantitative analysis of released NO, ONOO-and ROS free radicals in the hippocampus of the model rat, and the effect of cistanche deserticola polysaccharide administration on the released NO, ONOO-and ROS free radicals;
compared with the control group, the content of 3 free radicals in the rat hippocampus of the model group is up-regulated (P < 0.01), and compared with the model group, the content of 3 free radicals in the rat hippocampus of the cistanche low-medium-high dose group is obviously down-regulated (P < 0.01), and the specific results are shown in the table 3:
table 3-effect of cistanche polysaccharide on release of NO and ROS in hippocampus of AD rats:
| group of | NO | ONOO- |
| Normal group | 100±0 | 100±0 |
| False operation group | 100±0 | 100±0 |
| Model group | 187.38±21.78 | 286.79±24.37 |
| Low dose group | 156.21±19.24* | 212.35±19.56# |
| Medium dose group | 135.56±15.46* | 165.32±13.25# |
| High dose group | 110.23±9.25* | 114.38±5.37# |
Comparing #P with model group < 0.01; p <0.01 compared to the low dose group.
To sum up, it is known that:
experimental analysis proves that the cistanche deserticola polysaccharide can improve the learning and memory capacity of Alzheimer disease patients, strengthen the autoimmunity of the cistanche deserticola polysaccharide, and can be realized by reducing the damage of oxygen free radicals and accelerating the elimination of free radicals in the body, so that the cistanche deserticola polysaccharide has a certain effect of preventing senile dementia and has good application prospect.
The last points to be described are: while the invention has been described in detail in the foregoing general description and with reference to specific embodiments, the foregoing embodiments are merely illustrative of the technical aspects of the invention and are not limiting thereof; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (8)
1. A yang-strengthening health-preserving cistanche health-care product for preventing senile dementia is characterized by comprising the following raw materials:
50-60 parts of cistanche, 5-7 parts of medlar, 3-5 parts of epimedium, 3-6 parts of kudzuvine root, 3-7 parts of starch, 2-4 parts of sugar powder, 3-4 parts of magnesium stearate, 2-3 parts of microcrystalline cellulose and 1-2 parts of sodium carboxymethyl starch.
2. The preparation method of the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia as claimed in claim 1, which is characterized by comprising the following steps:
s1, firstly, preparing medicinal materials, namely preparing medlar extract, cistanche extract, epimedium extract and arrowroot, and respectively placing the medlar extract, the cistanche extract, the epimedium extract and the arrowroot in different containers for standby;
s2, uniformly mixing starch, powdered sugar, microcrystalline cellulose and sodium carboxymethyl starch, and sieving with a 80-mesh sieve to serve as auxiliary materials for later use;
s3, adding the auxiliary materials prepared in the S2 into the medlar extract, the cistanche extract, the epimedium extract and the arrowroot prepared in the S1, granulating, drying and tabletting to prepare finished tablets;
s4, polysaccharide extraction operation is carried out on the finished product tablets in the step S3, and experimental analysis is carried out.
3. The method for preparing the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the preparation method of the medlar extract in the step S1 is characterized by comprising the following steps:
5-7 parts of medlar are placed in a container, 10 times of water is added for ultrasonic extraction for 30min at 70 ℃, suction filtration is carried out, 8 times of water is added for ultrasonic extraction for 30min, suction filtration is carried out, 2 times of filtrate is combined, and the mixture is concentrated into 1g/ml extract.
4. The method for preparing the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the preparation method of the cistanche extract in the step S1 is characterized by comprising the following steps:
slicing 50-60 parts of cistanche deserticola, placing in a round bottom flask, adding 8 times of 70% ethanol, ultrasonically extracting for 45min, performing suction filtration, adding 6 times of 70% ethanol into residues, performing secondary extraction, performing suction filtration, mixing 2 times of filtrates, and concentrating to obtain extract of 1 g/ml.
5. The method for preparing the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the preparation method of the epimedium extract in the step S1 is characterized by comprising the following steps of:
placing 3-5 parts of herba Epimedii in a round bottom flask, adding 10 times of 70% ethanol, ultrasonic extracting for 30min, vacuum filtering, adding 8 times of 70% ethanol into the residue, extracting again, vacuum filtering, mixing 2 times of filtrates, and concentrating to obtain extract of 1 g/ml.
6. The method for preparing the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the step of preparing the arrowroot in the step S1 is as follows:
pulverizing 3-6 parts of radix Puerariae, and sieving with 80 mesh sieve.
7. The preparation method of the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the specific implementation steps of the S3 are as follows:
s301, adding the prepared auxiliary materials into medlar extract, cistanche extract, epimedium extract and arrowroot to be uniformly mixed, preparing soft materials, and granulating by a 18-mesh sieve to form wet granules;
s302, drying wet particles for 2 hours at 80 ℃ and sieving the wet particles with a 18-mesh sieve to obtain particles;
s303, adding sodium carboxymethyl starch and 0.2% magnesium stearate into the granules after the granule finishing, uniformly mixing, and tabletting.
8. The method for preparing the yang-strengthening health-preserving cistanche health-care product for preventing senile dementia according to claim 2, wherein the step of extracting the polysaccharide in the step S4 is implemented as follows:
s401, soaking the tablets in hot ethanol for 3 hours, filtering with gauze, discarding filtrate, and leaving residues;
s402, adding water into the generated residues to decoct for 3 times, each time for 1-2 hours, filtering and combining the filtrates;
s403, evaporating and concentrating the filtrate, centrifuging to remove sediment, precipitating supernatant with 95% ethanol with 2-3 times of volume, standing at 4deg.C for 24h, centrifuging at 4deg.C for 20min, centrifuging at 5500-6000r/min, and collecting sediment;
s404, re-dissolving the precipitate with water, deproteinizing, dialyzing, and freeze-drying to obtain crude polysaccharide;
s405, performing experimental analysis by using polysaccharide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310750321.2A CN116966233A (en) | 2023-06-21 | 2023-06-21 | Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310750321.2A CN116966233A (en) | 2023-06-21 | 2023-06-21 | Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116966233A true CN116966233A (en) | 2023-10-31 |
Family
ID=88473934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310750321.2A Pending CN116966233A (en) | 2023-06-21 | 2023-06-21 | Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116966233A (en) |
-
2023
- 2023-06-21 CN CN202310750321.2A patent/CN116966233A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN101205234B (en) | Curcumin-zinc compound as well as solid dispersion preparation and uses thereof | |
| CN108785328A (en) | Prevent or treat method and the bear gall powder used of entity tumor and hematological system tumor | |
| CN108635375A (en) | Prevent or treats hepatopathy and liver fibrosis and improve the bear gall powder and purposes of liver function | |
| CN108578433A (en) | For preventing or treating gall stone cholecystitis and improve the bear gall powder of gallbladder function | |
| CN107417556A (en) | L aspartase calciums and preparation method thereof | |
| CN109806382B (en) | A gallus Domesticus peptide composition and its application in preparing medicines for treating dysmenorrhea | |
| CN116966233A (en) | Yang-strengthening health-preserving cistanche health-care product for preventing senile dementia and preparation method thereof | |
| CN103432049B (en) | Composition with deodorization function | |
| CN112494598B (en) | Effective part composition for treating pharyngitis and application thereof | |
| CN114601865A (en) | Application of mulberry extract in preparation of medicine for treating ulcerative colitis | |
| CN106511394B (en) | Application of aspongopus fatty oil extract | |
| KR0185539B1 (en) | Complex coughing drug and their preparation method | |
| CN106880654B (en) | Application of panax japonicus extract in preparing medicine for treating rhinitis and composition | |
| JPH1192391A (en) | Pharmaceutical composition effective for preventing or treating dysmenorrhea | |
| CN112870290A (en) | Freckle-removing and depression-resolving composition and preparation method thereof | |
| CN111202841A (en) | Traditional Chinese medicine composition for improving body immunity and preparation method thereof | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN109364148A (en) | A kind of FUKE QIANJIN PIAN and preparation method thereof | |
| CN114949086B (en) | Composition for treating cerebral hemorrhage | |
| CN111643498B (en) | Pharmaceutical composition for treating kidney stone and application thereof | |
| CN104161799B (en) | Compound red sage root extract and its preparing method | |
| CN1240430C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing mthod thereof | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN115444924B (en) | Pearl oyster protein peptide composition and preparation and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |